Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Head and Neck Pathology
Published in: Head and Neck Pathology 2/2019

Open Access 01-06-2019 | Original Paper

Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers

Authors: Syed A. Khurram, Paul M. Speight

Published in: Head and Neck Pathology | Issue 2/2019

Login to get access

Abstract

DOG1 is an established diagnostic marker for gastrointestinal stromal tumours (GIST), but has been reported in salivary gland tumours (SGT) as an acinar and intercalated duct marker. However, its specificity and distribution is not well established. The aim of this study was to evaluate the diagnostic utility of DOG-1 expression in SGT in addition to comparing it with myoepithelial markers. Normal salivary tissue and SGT (n = 184) were examined for expression of DOG1 and a range of myoepithelial markers. SGT included: acinic cell carcinoma (ACC, n = 15), secretory carcinoma (SC, n = 9), pleomorphic adenoma (PA, n = 49), carcinoma ex-PA (Ca ex-PA, n = 11), adenoid cystic carcinoma (AdCC, n = 20), polymorphous adenocarcinoma (PAC, n = 6), myoepithelioma (n = 6), myoepithelial carcinoma (MC, n = 2), basal cell adenoma (BCA, n = 14), canalicular adenoma (CA, n = 19), mucoepidermoid carcinoma (MEC, n = 11), oncocytoma (n = 2), adenocarcinoma NOS (AdNOS, n = 4), basal cell adenocarcinoma (BCAC, n = 2), salivary duct carcinoma (SDC, n = 3) and papillary cystadenocarcinoma (PCAC, n = 1). Normal acini and ACC (14/15) showed strong luminal DOG1 staining; SC were largely negative with only focal expression in 3/9 cases. Luminal staining was seen in PA (14/49), PAC (4/6), Ca ex-PA (4/11) and AdCC (6/20). 8/11 MEC showed luminal and/or mucous cell staining. No staining was seen in myoepithelioma, MC, CA, adNOS and BCAC. BCA showed strong staining of myoepithelial cells in some cases (5/14). Variable myoepithelial DOG1 staining was seen in PA, Ca ex PA, BCA, SDC and PCAC which was not as consistent as myoepithelial markers such as calponin, p63 and αSMA. Absence of DOG1 can differentiate ACC from SC, but staining is variable in PA, PLGA and Ca ex-PA. Myoepithelial staining in some tumours but not in normal gland suggests a wider distribution in SGT than originally envisaged.
Literature
1.
Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, Varma S, Corless CL, Heinrich MC, Smith KS, Wang Z, Rubin B, Nielsen TO, Seitz RS, Ross DT, West RB, Cleary ML, van de Rijn M. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.CrossRefPubMed
2.
Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33(9):1401–8.CrossRefPubMed
3.
Wada T, Tanabe S, Ishido K, Higuchi K, Sasaki T, Katada C, Azuma M, Naruke A, Kim M, Koizumi W, Mikami T. DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach. World J Gastroenterol. 2013;19(47):9133–6.CrossRefPubMedPubMedCentral
4.
Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3661–70.CrossRefPubMedPubMedCentral
5.
Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee J, Lee B, Kim BM, Raouf R, Shin YK, Oh U. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008;455(7217):1210–5.CrossRef
6.
Chênevert J, Duvvuri U, Chiosea S, Dacic S, Cieply K, Kim J, Shiwarski D, Seethala RR. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012;25(7):919–29.CrossRefPubMed
7.
Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol. 2015;46(1):94–103.CrossRefPubMed
8.
Khurram SA, Sultan-Khan J, Atkey N, Speight PM. Cytogenetic and immunohistochemical characterisation of Mammary Analogue Secretory Carcinoma of Salivary glands. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(6):731–42.CrossRefPubMed
9.
Almaça J, Tian Y, Aldehni F, Ousingsawat J, Kongsuphol P, Rock JR, Harfe BD, Schreiber R, Kunzelmann K. TMEM16 proteins produce volume-regulated chloride currents that are reduced in mice lacking TMEM16A. J Biol Chem. 2009;284(42):28571–8.CrossRefPubMedPubMedCentral
10.
Skálová A, Vanecek T, Majewska H, Laco J, Grossmann P, Simpson RH, Hauer L, Andrle P, Hosticka L, Branžovský J, Michal M. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am J Surg Pathol. 2014;38(1):23–33.CrossRefPubMed
11.
Montalli VA, Passador-Santos F, Martinez EF, Furuse C, Aguiar MC, Soares FA, Soares AB, Brown AL, de Araújo NS, de Araújo VC. Mammaglobin and DOG-1 expression in polymorphous low-grade adenocarcinoma: an appraisal of its origin and morphology. J Oral Pathol Med. 2017;46(3):182–7.CrossRefPubMed
12.
El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of head and neck tumours. Lyon: ARC Press; 2017.
13.
Schmitt AC, Cohen C, Siddiqui MT. Expression of SOX10 in salivary gland oncocytic neoplasms: a review and a comparative analysis with other immunohistochemical markers. Acta Cytol. 2015;59(5):384–90.CrossRefPubMed
14.
Pinto A, Nosé V, Rojas C, Fan YS, Gomez-Fernandez C. Searching for mammary analogue [corrected] secretory carcinoma of salivary gland among its mimics. Mod Pathol. 2014;27(1):30–7.CrossRefPubMed
15.
Naous R, Zhang S, Valente A, Stemmer M, Khurana KK. Utility of immunohistochemistry and ETV6 (12p13) gene rearrangement in identifying secretory carcinoma of salivary gland among previously diagnosed cases of acinic cell carcinoma. Pathol Res Int. 2017;2017:1497023.CrossRef
16.
Said-Al-Naief N, Carlos R, Vance GH, Miller C, Edwards PC. Combined DOG1 and mammaglobin immunohistochemistry is comparable to ETV6-breakapart analysis for differentiating between papillary cystic variants of acinic cell carcinoma and mammary analogue secretory carcinoma. Int J Surg Pathol. 2017;25(2):127–40.CrossRefPubMed
17.
Canberk S, Onenerk M, Sayman E, Goret CC, Erkan M, Atasoy T, Kilicoglu GZ. Is DOG1 really useful in the diagnosis of salivary gland acinic cell carcinoma?—a DOG1 (clone K9) analysis in fine needle aspiration cell blocks and the review of the literature. CytoJournal. 2015;12:18.CrossRefPubMedPubMedCentral
18.
Stevens TM, Kovalovsky AO, Velosa C, Shi Q, Dai Q, Owen RP, Bell WC, Wei S, Althof PA, Sanmann JN, Sweeny L, Carroll WR, Siegal GP, Bullock MJ, Brandwein-Gensler M. Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. Mod Pathol. 2015;28(8):1084–100.CrossRefPubMed
19.
Abd Raboh NM, Hakim SA. Diagnostic role of DOG1 and p63 immunohistochemistry in salivary gland carcinomas. Int J Clin Exp Pathol. 2015;8(8):9214–22.PubMedPubMedCentral
20.
Montalli VA, Martinez E, Tincani A, Martins A, Abreu Mdo C, Neves C, Costa AF, Araújo VC, Altemani A. Tubular variant of basal cell adenoma shares immunophenotypical features with normal intercalated ducts and is closely related to intercalated duct lesions of salivary gland. Histopathology. 2014;64(6):880–9.CrossRefPubMed
21.
Zhu S, Schuerch C, Hunt J. Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med. 2015;139(1):55–66.CrossRefPubMed
22.
Laco J, Švajdler M Jr, Andrejs J, Hrubala D, Hácová M, Vaněček T, Skálová A, Ryška A. Mammary analog secretory carcinoma of salivary glands: a report of 2 cases with expression of basal/myoepithelial markers (calponin, CD10 and p63 protein). Pathol Res Pract. 2013;209(3):167–72.CrossRefPubMed
23.
Bishop JA, Yonescu R, Batista D, Begum S, Eisele DW, Westra WH. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Hum Pathol. 2013;44(10):1982–8.CrossRefPubMedPubMedCentral
24.
Sethi R, Kozin E, Remenschneider A, Meier J, VanderLaan P, Faquin W, Deschler D, Frankenthaler R. Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy. Laryngoscope. 2014;124(1):188–95.CrossRefPubMed
25.
Mariano FV, dos Santos HT, Azañero WD, da Cunha IW, Coutinho-Camilo CM, de Almeida OP, Kowalski LP, Altemani A. Mammary analogue secretory carcinoma of salivary glands is a lipid-rich tumour, and adipophilin can be valuable in its identification. Histopathology. 2013;63(4):558–67.PubMed
26.
Luo W, Lindley SW, Lindley PH, Krempl GA, Seethala RR, Fung KM. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature. Int J Clin Exp Pathol. 2014;7(12):9008–22.PubMedPubMedCentral
27.
Shah AA, Wenig BM, LeGallo RD, Mills SE, Stelow EB. Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma. Head Neck Pathol. 2015;9(1):85–95.CrossRefPubMed
28.
Furuse C, Sousa SO, Nunes FD, Magalhães MH, Araújo VC. Myoepithelial cell markers in salivary gland neoplasms. Int J Surg Pathol. 2005;13(1):57–65.CrossRefPubMed
29.
Santos EP, Cavalcante DR, Melo AU, Pereira JC, Gomes MZ, Albuquerque RL Jr. Plasmacytoid myoepithelioma of minor salivary glands: report of case with emphasis in the immunohistochemical findings. Head Face Med. 2011;7:24.CrossRefPubMedPubMedCentral
30.
Cavalcante RB, Lopes FF, Ferreira AS, Freitas RDA, de Souza LB. Immunohistochemical expression of vimentin, calponin and HHF-35 in salivary gland tumors. Braz Dent J. 2007;18(3):192–7.CrossRefPubMed
31.
Zhao J, Wang J, Yu C, Guo L, Wang K, Liang Z, Lou J. Prognostic factors affecting the clinical outcome of carcinoma ex pleomorphic adenoma in the major salivary gland. World J Surg Oncol. 2013;11(1):180.CrossRefPubMedPubMedCentral
32.
Di Palma S, Lambros MB, Savage K, Jones C, Mackay A, Dexter T, Iravani M, Fenwick K, Ashworth A, Reis-Filho JS. Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells. J Clin Pathol. 2007;60(5):492–9.CrossRefPubMed
33.
34.
Simpson RH, Skálová A, Di Palma S, Leivo I. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch. 2014;465(4):371–84.CrossRefPubMed
35.
Araújo V, Sousa S, Jaeger M, Jaeger R, Loyola A, Crivelini M, Araújo N. Characterization of the cellular component of polymorphous low-grade adenocarcinoma by immunohistochemistry and electron microscopy. Oral Oncol. 1999;35(2):164–72.CrossRefPubMed
36.
Perez-Ordonez B, Linkov I, Huvos AG. Polymorphous low-grade adenocarcinoma of minor salivary glands: a study of 17 cases with emphasis on cell differentiation. Histopathology. 1998;32(6):521–9.CrossRefPubMed
37.
Rooper L, Sharma R, Bishop JA. Polymorphous low grade adenocarcinoma has a consistent p63+/p40- immunophenotype that helps distinguish it from adenoid cystic carcinoma and cellular pleomorphic adenoma. Head Neck Pathol. 2015;9(1):79–84.CrossRefPubMed
Metadata
Title
Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers
Authors
Syed A. Khurram
Paul M. Speight
Publication date
01-06-2019
Publisher
Springer US
Published in
Head and Neck Pathology / Issue 2/2019
Electronic ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-018-0917-3

Other articles of this Issue 2/2019

Head and Neck Pathology 2/2019 Go to the issue

Original Paper

Sclerosing Microcystic Adenocarcinoma: Report of a Rare Case and Review of Literature

Case Report

Sporadic Minute Pharyngeal Xanthomas Detected Incidentally During Esophagogastroduodenoscopy: A Case Series

Original Paper

Palatal Polymorphous Adenocarcinoma with High-Grade Transformation: A Case Report and Literature Review

Sine qua non Clinicopathologic Correlation

Sinonasal Ameloblastoma

Original Paper

Primordial Odontogenic Tumor: Report of a New Case and Literature Review

Original Paper

Clear Cell Odontogenic Carcinoma: Occurrence of EWSR1-CREB1 as Alternative Fusion Gene to EWSR1-ATF1